Radiotherapy plays an important part in the management of breast cancer. Especially after breast-conserving surgery, external whole breast irradiation, occasionally with an additional local boost, is an integral part of breast conservation. Besides external radiation techniques, brachytherapy (BT) has long been among the treatment options, especially with regard to local boost application. With the emerging implementation of accelerated partial breast irradiation (APBI), BT in general and interstitial multi-catheter BT in particular, are gaining an increasing role in the management of a selected group of early breast cancer patients. APBI is an approach to reduce the irradiated area to the former tumor bed rather than treating the whole breast tissue in patients with a low baseline local recurrence risk. After a variety of phase I-III clinical studies, it is clearly evident that APBI will play a role in the treatment of this selected patient group. In this review, we focus on the clinical development and different available techniques of breast BT and provide a preview of prospects for its use.
5 August 2025 in memo - Magazine of European Medical Oncology
Summary: Radiotherapy is an integral part of multidisciplinary adjuvant treatment for early breast cancer and is recommended in a high percentage of patients following breast-conserving surgery or mastectomy, particularly those with specific risk factors. Due to diagnostic and clinical developments, tumour characteristics and the risk of relapse can now be assessed more precisely, putting the era of ‘one-size-fits-all’ radiotherapy treatments behind us. Consideration of all the advantages and disadvantages of breast radiotherapy, including acute and long-term side effects, makes risk-adapted and tailored treatment necessary. Continuous technical improvements allow better dose distribution in the target and better sparing of organs at risk with a possible de-escalation in treatment time with moderate and ultrahypofractionation. Incorporating molecular markers for better estimation of the local recurrence risk facilitates decision-making for the use of partial breast irradiation or even the complete omission of irradiation. In this short review, modern strategies of de-escalation in early breast radiotherapy are discussed without a claim of completeness and reflects the personal choice of the author.
Second breast conserving treatment (2ndBCT) has emerged as an option for patients with low-risk second ipsilateral breast cancer event (2ndiBCE) after prior breast BCT combining lumpectomy and irradiation. However, HER2-positive (HER2+) and triple-negative (TN) subtypes are considered poor candidates for 2ndBCT. We evaluated oncologic outcomes after 2ndBCT versus mastectomy in high-risk 2ndiBCE. We performed a propensity score-matched cohort study of patients diagnosed with 2ndiBCE between 1995 and 2017. Data were collected from 15 centers across seven European countries. Patients underwent mastectomy or lumpectomy plus Multicatheter-interstitial brachytherapy (MIB). One-to-one matching used ten clinicopathologic variables. The primary endpoint was 5-year overall survival (OS). Secondary endpoints included 5-year cumulative incidence of third breast events, regional relapse, distant metastasis, disease-free survival (DFS) and cause-specific survival (CSS). Among 1327 patients (Mastectomy 945; 2ndBCT 382), 241 were matched (Mastectomy versus 2ndBCT): HER2+ 70/62 and TN 55/54. Median tumour size (mm) for mastectomy versus 2ndBCT was 17/13 in HER2+ and 13/12 in TN. Median follow-up was 79.9 and 80.5 months for HER2+ and TN, respectively, without group differences. No statistical differences in 5-year OS were observed between mastectomy and 2ndBCT (HER2+: 85% vs 79%, p = 0.85; TN: 89% vs 81%, p = 0.4). Similarly, the secondary endpoints were also comparable between groups. This first matched comparison of mastectomy and 2ndBCT with MIB in patients with HER2+ and TN tumours did not identify clear differences in efficacy. Given the limited sample size, 2ndBCT may warrant consideration in selected patients seeking breast preservation.
Purpose: Male breast cancer (maleBC) is an orphan disease. Aside from age, risk factors include genetic mutations and conditions like Klinefelter syndrome or other reasons of hypogonadism. Treatment is based on standards in women, but biological differences may exist, with maleBC exhibiting higher rates of hormone-receptor expression. Limiting data exists regarding the rate of low/ultralow HER2 expression, a predictive biomarker for the antibody–drug conjugate (ADC) trastuzumab deruxtecan (T-DXd) in HER2-negative disease in women. Materials and Methods: We conducted a retrospective single-center analysis of clinicopathological features of maleBC at a tertiary cancer center. We identified a cohort of 57 maleBC patients, described demographic, pathological, prognostic and surgical and systemic treatment data and evaluated frequencies of low and ultralow HER2 expression. Results: The mean age was 64.3 (SE ± 1.79) years; 94.7% (n = 54) of patients presented with early/nonmetastatic breast cancer and 40.7% (22 of 54) of patients exhibited nodal involvement. Most patients (92.6%, 50 of 54 patients) had luminal disease and approximately one third of patients received chemotherapy. Endocrine therapy was administered in 87.7% (n = 50/57) of cases. For 52 of the patients included, full receptor status data including HER2 IHC scoring and/or histological specimens were available. IHC slides of tumor specimens from 24 patients with either historically reported “HER2 negative” or “HER2 0” expression were available for reassessment; 79.2% (n = 19 of 24) of these tumors exhibited either HER2-low or -ultralow expression. In the whole cohort, rates of HER2-low and -ultralow expression were 75.0% (39 of 52) and 5.8% (3 of 52 patients), respectively. The median follow-up was 7 years. Six deaths occurred in the total population (n = 57). The median event-free survival (EFS) was 8.39 years (95% CI 7.36–11.35). No statistically significant associations were observed between HER2 expression categories and clinicopathological variables including grade, ER status, nodal status, genetic variant status, age, Ki67 index, or overall survival events. Conclusions: In this cohort of maleBC patients, high rates of combined HER2-low and -ultralow expression were observed upon reassessment of tumors with historically negative HER2 status, shedding light on potential ADC eligibility in male breast cancer.